Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M

Mirum Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.54 revenue$69,222,000

Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).
FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.
Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.
Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.
Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $69.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001759425-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.